PetMeds Names New CEO, Rebuilds Board Amid Takeover Fight

A takeover bid worth three dollars a share has sat untouched since June, and the board it is aimed at just replaced nearly its entire leadership table anyway. PetMeds swore in a new chief executive this month, handed the board chair to a Shake Shack technology executive, and added a culture-and-talent specialist as its newest independent director — the most sweeping reset the embattled pet pharmacy has attempted since the SilverCape standoff began.

PetMeds names Willard CEO, adds two directors

PetMeds confirmed the reshuffle in two announcements eight days apart. On September 17th, the company said Jeff Willard will become chief executive and president effective September 28th, succeeding Leslie Campbell, who has run PetMeds as interim CEO since August 2025 and will retire as board chair the same day. Campbell stays on for 60 days as a strategic advisor. Justin Mennen, PetMeds’ lead independent director and chief information and technology officer at Shake Shack, takes over as chair.

Willard spent 25 years in consumer and e-commerce leadership, most recently as chief executive of Stewart-MacDonald, and before that held roles at Casper, Simmons Bedding, Harman International, Coleman, Helen of Troy, and Lexmark. “My primary focus now is on sharpening our execution and establishing a direct, clear path back to sustainable profitability and growth,” he said in the announcement.

On September 21st, PetMeds added a third new face. Tamar Elkeles joins as an independent director and chair of the compensation and human capital committee, effective the same September 17th date as Willard’s appointment. Elkeles spent more than two decades as chief learning and talent officer at Qualcomm, where she helped the company scale from $100 million to more than $25 billion in revenue and from 700 to 35,000 employees. She currently advises East Wind Advisors, 444 Capital, and Emerge Capital, and sits on the boards of Brightline Interactive and Open Sesame.

What a full board reset signals to SilverCape

None of the three new leaders has any prior tie to PetMeds, and that is very likely the point. SilverCape Investments has spent months publicly framing the board as an entrenched group defending a shrinking business rather than negotiating over its revised $3-a-share buyout proposal, a bid that has sat unanswered since June. A board that wanted to prove SilverCape wrong could not simply promote from within. It needed outsiders with resumes activist investors and proxy advisors would recognize on sight.

Willard’s background fits a specific profile: a turnaround operator who has run consumer brands through structural pressure before, at Casper, Coleman, and Helen of Troy, categories that faced the same direct-to-consumer and big-box competition PetMeds is up against now. That is a different kind of hire than simply making Campbell’s role permanent would have been. Campbell’s interim tenure produced the numbers PetMeds has been citing as proof of a turnaround, a narrower net loss and lower customer acquisition costs even as revenue kept falling. But interim and narrowing are not the same case continuity-minded investors want to hear.

Mennen’s day job at Shake Shack and Elkeles’ three decades running human capital strategy at Qualcomm send a related signal. Installing a sitting public-company technology executive as chair and a culture-and-talent specialist as compensation committee chair reads like a board building the governance credibility that a serious buyer, or a serious rejection of one, requires. It is the kind of move a board makes when it needs SilverCape and every other shareholder watching to believe the next chapter will be run differently than the last several quarters were, not merely narrated differently by the same people.

There’s a specific tell in Elkeles landing atop the compensation committee rather than elsewhere on the board. Activist campaigns frequently turn executive pay into a proxy fight, arguing incumbent leadership is overcompensated relative to shareholder returns. Handing that committee to someone who spent decades designing compensation and workforce strategy at a company that scaled fortyfold gives PetMeds a credentialed answer if SilverCape goes that route next.

The timing reinforces that read. This reset lands five weeks after PetMeds signed a $37 million sale-leaseback on its own headquarters to shore up cash. A company confident it can outlast an activist siege on operating cash flow alone does not typically also lean on its real estate. Three new leaders and a freed-up balance sheet, arriving in the same stretch, look less like unrelated housekeeping and more like a board assembling every asset it has in a fight it may be losing on its own.

What Willard’s first quarter needs to prove

Willard’s own words set the bar he will be measured against: “a direct, clear path back to sustainable profitability and growth.” His first real test is the next quarterly print, and whether it shows revenue decline slowing from the 19.9% drop PetMeds posted last quarter or simply repeats it.

Two other checkpoints sit ahead of that. The sale-leaseback is expected to close by late November, and whether the proceeds go toward debt, marketing, or a cash cushion will say more about strategy than the announcement did. SilverCape, for its part, has said nothing publicly since its revised offer went unanswered in June.

Three fresh names atop PetMeds do not obligate a response from SilverCape. But a firm that has spent months accusing the board of stalling now has a genuinely different board in front of it, not the same people it built its case against. The open question is not whether Willard can run PetMeds better than an interim caretaker could. It is whether new leadership alone is enough to change SilverCape’s math, or whether $3 a share still looks like a ceiling rather than a floor.

Source: PetMeds via GlobeNewswire